These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 23600715)

  • 1. Trajectories of antipsychotic response in drug-naive schizophrenia patients: results from the 6-month ESPASS follow-up study.
    Nordon C; Rouillon F; Azorin JM; Barry C; Urbach M; Falissard B
    Acta Psychiatr Scand; 2014 Feb; 129(2):116-25. PubMed ID: 23600715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
    Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trajectories and antecedents of treatment response over time in early-episode psychosis.
    Levine SZ; Rabinowitz J
    Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study.
    Levine SZ; Rabinowitz J; Case M; Ascher-Svanum H
    J Clin Psychopharmacol; 2010 Aug; 30(4):446-9. PubMed ID: 20631562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories.
    Levine SZ; Leucht S
    Biol Psychiatry; 2010 Jul; 68(1):86-92. PubMed ID: 20227681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials.
    Levine SZ; Leucht S
    Schizophr Res; 2014 Jun; 156(1):107-14. PubMed ID: 24794879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response trajectories in "real-world" naturalistically treated schizophrenia patients.
    Schennach R; Meyer S; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Musil R; Möller HJ; Riedel M
    Schizophr Res; 2012 Aug; 139(1-3):218-24. PubMed ID: 22658528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The psychopathological characteristics of treatment discontinuation group in 6-month treatment with paliperidone ER.
    Thavichachart N; Kongsakon R; Lo WT; Lim L; Singh S; Sobrevega E; Banaag C; Bautista J; Evangelista ML; Dimatalac B; Choi A; Nerapusee O
    Int J Clin Pract; 2012 Oct; 66(10):969-75. PubMed ID: 22994331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A global measure to assess switching antipsychotic medications in the treatment of schizophrenia.
    Targum SD; Pestreich L; Reksoprodjo P; Pereira H; Guindon C; Hochfeld M
    Hum Psychopharmacol; 2012 Sep; 27(5):455-63. PubMed ID: 22826027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany.
    Stargardt T; Edel MA; Ebert A; Busse R; Juckel G; Gericke CA
    J Clin Psychopharmacol; 2012 Oct; 32(5):602-7. PubMed ID: 22926592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients.
    Karagianis J; Novick D; Pecenak J; Haro JM; Dossenbach M; Treuer T; Montgomery W; Walton R; Lowry AJ
    Int J Clin Pract; 2009 Nov; 63(11):1578-88. PubMed ID: 19780867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice].
    Cousin FR; Samuelian JC; Saoud M; Schmitt L; Vacheron MN; Vidailhet P; Augendre J; Walter M; Tonelli I; Pascal JC
    Encephale; 2012 Feb; 38(1):64-74. PubMed ID: 22381726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study.
    Tenback DE; van Harten PN; Slooff CJ; van Os J;
    Compr Psychiatry; 2007; 48(5):436-40. PubMed ID: 17707251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.
    Emsley R; Oosthuizen PP; Koen L; Niehaus DJ; Martinez G
    J Clin Psychiatry; 2012 Apr; 73(4):e541-7. PubMed ID: 22579160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
    Honer WG; Kopala LC; Rabinowitz J
    J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.